Supplementation of a novel microbial biopolymer, PGB1, from new Enterobacter sp. BL-2 delays the deterioration of type 2 diabetic mice.
Antidiabetic effects of a novel microbial biopolymer (PGB)1 excreted from new Enterobacter sp. BL-2 were tested in the db/db mice. The animals were divided into normal control, rosiglitazone (0.005%, wt/wt), low PGB1 (0.1%, wt/wt), and high PGB1 (0.25%, wt/wt) groups. After 5 weeks, the blood glucose levels of high PGB1 and rosiglitazone supplemented groups were significantly lower than those of the control group. In hepatic glucose metabolic enzyme activities, the glucokinase activities of PGB1 supplemented groups were significantly higher than the control group, whereas the PEPCK activities were significantly lower. The plasma insulin and hepatic glycogen levels of the low and high PGB1 supplemented groups were significantly higher compared with the control group. Specifically, the insulin and glycogen increases were dose-responsive to PGB1 supplement. PGB1 supplement did not affect the IPGTT and IPITT compared with the control group; however, rosiglitazone significantly improved IPITT. High PGB1 and rosiglitazone supplementation preserved the appearance of islets and insulin-positive cells in immunohistochemical photographs of the pancreas compared with the control group. These results demonstrated that high PGB1 (0.25% in the diet) supplementation seemingly contributes to preventing the onset and progression of type 2 diabetes by stimulating insulin secretion and enhancing the hepatic glucose metabolic enzyme activities.
Yeo
Jiyoung
J
Department of Food Science and Nutrition, Department of Genetic Engineering, Institute of Genetic Engineering, Kyungpook National University, Daegu 702-701, Korea.
Lee
Yong-Hyun
YH
Jeon
Seon-Min
SM
Jung
Un Ju
UJ
Lee
Mi-Kyung
MK
Jung
Young-Mi
YM
Choi
Myung-Sook
MS
D000818:Animals; D001704:Biopolymers / Q000302:isolation & purification / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019587:Dietary Supplements; D004754:Enterobacter / Q000737:chemistry*; D005944:Glucosamine / Q000494:pharmacology*; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D007150:Immunohistochemistry; D007328:Insulin / Q000097:blood; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010179:Pancreas / Q000473:pathology; D011897:Random Allocation; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology
D001704:Biopolymers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005944:Glucosamine